In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body ...
The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular ...
About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...
The Biden administration has proposed a new plan to expand coverage of glucagon-like peptide-1 (GLP-1) medications such as ...
The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.
The Centers for Medicare and Medicaid Services draft regulation also would introduce Medicare and Medicaid coverage of ...
TennCare is federally required to cover GLP-1 drugs; of the $118M in the cost increase request, more than $76 million would ...
GLP-1RA dispensing has increased from 2022 and 2023, whereas metabolic bariatric surgery has decreased among individuals with obesity.
If made official, the proposed rule would give Part D and Medicaid beneficiaries expanded coverage to antiobesity drugs ...
A multistate model that enables real-time risk recalculations may help improve risk stratification for prediction of ...
Semaglutide and liraglutide are associated with a reduced risk for hospitalization due to alcohol use disorder (AUD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback